Type I IFN innate immune response to adenovirus-mediated IFN-γ gene transfer contributes to the regression of cutaneous lymphomas

Journal of Clinical Investigation

Volumn 117, Issue 10, 2007, Pages 2834-2846

  Urosevic, Mirjana ^a   Fujii, Kazuyasu ^a,c   Calmels, Bastien ^b   Laine, Elisabeth ^a   Kobert, Nikita ^a   Acres, Bruce ^b   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRANSGENE S A   (France)

^c OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; GAMMA INTERFERON; INTERFERON; TG 1042; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GENE INSERTION; GENE TRANSFER; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; REMISSION; SKIN DEFECT; SKIN LYMPHOMA; TUMOR BIOPSY;

ADENOVIRIDAE; CELLS, CULTURED; GENE EXPRESSION PROFILING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNITY, NATURAL; INTERFERON TYPE I; INTERFERON TYPE II; LYMPHOMA; SKIN NEOPLASMS;

EID: 34948842060     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI32077     Document Type: Article

References (70)

1. Dummer, R., Cozzio, A., and Urosevic, M. 2006. Pathogenesis and therapy of cutaneous lymphomasprogress or impasse? Exp. Dermatol. 15:392-400.
2. Dummer, R., et al. 2006. Standard and experimental therapy in cutaneous T-cell lymphomas. J. Cutan. Pathol. 33(Suppl. 1):52-57.
3. Dummer, R., et al. 2004. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood. 104:1631-1638.
4. McConnell, M.J., and Imperiale, M.J. 2004. Biology of adenovirus and its use as a vector for gene therapy. Hum. Gene Ther. 15:1022-1033.
5. Bessis, N., GarciaCozar, F.J., and Boissier, M.C. 2004. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther. 11(Suppl. 1):S10-S17.
6. Muruve, D.A. 2004. The innate immune response to adenovirus vectors. Hum. Gene Ther. 15:1157-1166.
7. Dunn, G.P., Koebel, C.M., and Schreiber, R.D. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6:836-848.
8. Katze, M.G., He, Y., and Gale, M., Jr. 2002. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2:675-687.
9. Kunzi, M.S., and Pitha, P.M. 2003. Interferon targeted genes in host defense. Autoimmunity. 36:457-461.
10. Ritchie, K.J., and Zhang, D.E. 2004. ISG15: the immunological kin of ubiquitin. Semin. Cell Dev. Biol. 15:237-246.
11. Martensen, P.M., and Justesen, J. 2004. Small ISGs coming forward. J. Interferon Cytokine Res. 24:1-19.
12. Cole, K.E., et al. 1998. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 187:2009-2021.
13. Jaffe, E.A., et al. 1989. IFN-gamma and IFN-alpha induce the expression and synthesis of Leu 13 antigen by cultured human endothelial cells. J. Immunol. 143:3961-3966.
14. Bas, A., Forsberg, G., Hammarstrom, S., and Hammarstrom, M.L. 2004. Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3- phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. Scand. J. Immunol. 59:566-573.
15. Dummer, R., et al. 2001. Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication. Blood. 97:523-527.
16. Sun, W.H., et al. 1998. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood. 91:570-576.
17. Tracey, L., et al. 2004. Transcriptional response of T cells to IFN-alpha: changes induced in IFN-alpha-sensitive and resistant cutaneous T cell lymphoma. J. Interferon Cytokine Res. 24:185-195.
18. Tracey, L., et al. 2002. Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am. J. Pathol. 161:1825-1837.
19. Platanias, L.C. 2005. Mechanisms of type-I- and type-II-interferon- mediated signalling. Nat. Rev. Immunol. 5:375-386.
20. Honda, K., et al. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature. 434:772-777.
21. Kawai, T., et al. 2004. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5:1061-1068.
22. Huarte, E., et al. 2006. Recombinant adenoviral vectors turn on the type I interferon system without inhibition of transgene expression and viral replication. Mol. Ther. 14:129-138.
23. Li, S., et al. 2005. Induction of IFN-regulated factors and antitumoral surveillance by transfected placebo plasmid DNA. Mol. Ther. 11:112-119.
24. Cerullo, V., et al. 2007. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol. Ther. 15:378-385.
25. Hartman, Z.C., et al. 2007. Adenovirus infection triggers a rapid, MyD88 regulated, transcriptome response critical to acute phase and adaptive immune responses in vivo. J. Virol. 81:1796-1812.
26. Zhu, J., Huang, X., and Yang, Y. 2007. Innate immune response to adenoviral vectors is mediated by both TLR-dependent and -independent pathways. J. Virol. 81:3170-3180.
27. Wagner, H., and Bauer, S. 2006. All is not Toll: new pathways in DNA recognition. J. Exp. Med. 203:265-268.
28. Hensley, S.E., Giles-Davis, W., McCoy, K.C., Weninger, W., and Ertl, H.C. 2005. Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J. Immunol. 175:6032-6041.
29. Geutskens, S.B., et al. 2000. Recombinant adenoviral vectors have adjuvant activity and stimulate T cell responses against tumor cells. Gene Ther. 7:1410-1416.
30. Molinier-Frenkel, V., et al. 2002. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 76:127-135.
31. Ruzek, M.C., Kavanagh, B.F., Scaria, A., Richards, S.M., and Garman, R.D. 2002. Adenoviral vectors stimulate murine natural killer cell responses and demonstrate antitumor activities in the absence of transgene expression. Mol. Ther. 5:115-124.
32. Reich, N., Pine, R., Levy, D., and Darnell, J.E., Jr. 1988. Transcription of interferon-stimulated genes is induced by adenovirus particles but is suppressed by E1A gene products. J. Virol. 62:114-119.
33. Hartman, Z.C., Black, E.P., and Amalfitano, A. 2007. Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. Virology. 358:357-372.
34. Scibetta, A.G., Copier, J., Barrett, A., Chaplin, T., and Taylor-Papadimitriou, J. 2005. Gene expression changes induced by a recombinant E1-/E3-adenovirus type 5 vector in human mammary epithelial cells. Intervirology. 48:350-361.
35. Rao, X.M., et al. 2006. Gene expression profiles of normal human lung cells affected by adenoviral E1B. Virology. 350:418-428.
36. Stilwell, J.L., McCarty, D.M., Negishi, A., Superfine, R., and Samulski, R.J. 2003. Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression. J. Virol. 77:12881-12885.
37. Thach, D.C., et al. 2005. Surveillance of transcriptomes in basic military trainees with normal, febrile respiratory illness, and convalescent phenotypes. Genes Immun. 6:588-595.
38. Urosevic, M., et al. 2005. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J. Natl. Cancer Inst. 97:1143-1153.
39. Urosevic, M., et al. 2004. Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Clin. Cancer Res. 10:4959-4970.
40. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer. 5:263-274.
41. Tsan, M.F. 2006. Toll-like receptors, inflammation and cancer. Semin. Cancer Biol. 16:32-37.
42. Killeen, S.D., Wang, J.H., Andrews, E.J., and Redmond, H.P. 2006. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br. J. Cancer. 95:247-252.
43. Schroder, K., Hertzog, P.J., Ravasi, T., and Hume, D.A. 2004. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75:163-189.
44. Wysocka, M., et al. 2004. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood. 104:4142-4149.
45. Wysocka, M., et al. 2006. Imidazoquinolines are toll receptor agonists which potently and broadly enhance the cellular immune response of immunodepressed cutaneous T-cell lymphoma patients: synergy with interferon gamma and IL-18 [abstract]. J. Invest. Dermatol. 126:38.
46. Sun, D., and Ding, A. 2006. MyD88-mediated stabilization of interferon-gamma-induced cytokine and chemokine mRNA. Nat. Immunol. 7:375-381.
47. Schroder, K., Sweet, M.J., and Hume, D.A. 2006. Signal integration between IFNgamma and TLR signalling pathways in macrophages. Immunobiology. 211:511-524.
48. Der, S.D., Zhou, A., Williams, B.R., and Silverman, R.H. 1998. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. U. S. A. 95:15623-15628.
49. Urosevic, M., et al. 2005. CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. Hum. Pathol. 36:1020-1024.
50. Wenzel, J., et al. 2005. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J. Pathol. 205:435-442.
51. Zhao, C., Denison, C., Huibregtse, J.M., Gygi, S., and Krug, R.M. 2005. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc. Natl. Acad. Sci. U. S. A. 102:10200-10205.
52. Rani, M.R., Hibbert, L., Sizemore, N., Stark, G.R., and Ransohoff, R.M. 2002. Requirement of phosphoinositide 3-kinase and Akt for interferon-beta- mediated induction of the beta-R1 (SCYB11) gene. J. Biol. Chem. 277:38456-38461.
53. Strieter, R.M., et al. 2006. Cancer CXC chemokine networks and tumour angiogenesis. Eur. J. Cancer. 42:768-778.
54. Deblandre, G.A., et al. 1995. Expression cloning of an interferon-inducible 17-kDa membrane protein implicated in the control of cell growth. J. Biol. Chem. 270:23860-23866.
55. Evans, S.S., Collea, R.P., Leasure, J.A., and Lee, D.B. 1993. IFN-alpha induces homotypic adhesion and Leu-13 expression in human B lymphoid cells. J. Immunol. 150:736-747.
56. Yang, G., Xu, Y., Chen, X., and Hu, G. 2006. IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene. 26:594-603.
57. Brierley, M.M., and Fish, E.N. 2005. Stats: multifaceted regulators of transcription. J. Interferon Cytokine Res. 25:733-744.
58. Garcia-Sastre, A., and Biron, C.A. 2006. Type 1 interferons and the virus-host relationship: a lesson in detente. Science. 312:879-882.
59. Yoshimura, A. 2006. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 97:439-447.
60. Dai, Y., et al. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. U. S. A. 92:1401-1405.
61. Liu, Y.J. 2005. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23:275-306.
62. Shechter, Y., Preciado-Patt, L., Schreiber, G., and Fridkin, M. 2001. Prolonging the half-life of human interferon-alpha 2 in circulation: design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl) 7-interferon-alpha 2. Proc. Natl. Acad. Sci. U. S. A. 98:1212-1217.
63. Platanias, L.C., and Fish, E.N. 1999. Signaling pathways activated by interferons. Exp. Hematol. 27:1583-1592.
64. Takaoka, A., and Yanai, H. 2006. Interferon signalling network in innate defence. Cell. Microbiol. 8:907-922.
65. Liu, G., et al. 2003. NetAffx: Affymetrix probesets and annotations. Nucleic Acids Res. 31:82-86.
66. Brown, M.P., et al. 2000. Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc. Natl. Acad. Sci. U. S. A. 97:262-267.
67. Martinelli, S., et al. 2004. Induction of genes mediating interferon-dependent extracellular traps formation during neutrophil differentiation. J. Biol. Chem. 279:44123-44132.
68. Fah, J., Pavlovic, J., and Burg, G. 1995. Expression of MxA protein in inflammatory dermatoses. J. Histochem. Cytochem. 43:47-52.
69. Tusher, V.G., Tibshirani, R., and Chu, G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U. S. A. 98:5116-5121.
70. Slos, P., De Meyer, M., Leroy, P., Rousseau, C., and Acres, B. 2001. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity. Cancer Gene Ther. 8:321-332.